Open to CEO, Founder, Co-Founder, President, Chairman or c-suite executive (CFO, CBO, CCO, CSO, CMO) of US-based, post-series A-funded, therapeutic Biotech companies.
Free to attend, pre-registration only, Chatham House Rule forum hosted on Zoom where all participants are active discussants.
Agenda (All times in EDT)
Josh Dance, SVP, LSX
Introduction from LSX to the forum, introductions from all participants and sharing of pre-event benchmarking survey results
Moderator: Ed Saltzman, Executive Chairman, Cello Health Bio Consulting
13:10 Client Alliance Perspective Fireside Chat: Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy And Strategic Partnering
Unlike single- or few-asset companies, which have a relatively straight forward path to value, based primarily on executing clinical development and progressively de-risking the asset(s), broad platform companies have a “good problem” - they have a plethora of pipeline opportunities. While companies developing a limited number of assets can, and typically do, choose to progress these assets as far as possible towards PoC prior to partnering, companies working on wresting value out of broad discovery platforms will often confront partnering strategy decisions much sooner. Sometimes this can be as early as after initial funding and, in most cases, prior to clinical data. The need to partner early both pushes corporate strategy to the forefront, and elevates the importance of partner selection being likely that ongoing strategic collaboration will be a key element of any deal.
Platform companies must make sound strategic choices about platform validation, prioritize and sequence targets and indications, and about what to advance to market or future value inflection alone, and when to partner without cannibalizing retained programs, or restricting future opportunities.
Ed Saltzman, Executive Chairman, Cello Health Bio Consulting
R.A. Session, President, CEO & Founder, Taysha Gene Therapies
13:30 Executive Led Discussion: Going Public & The Dynamic of Crossover Investment
Chen Yu, Managing Partner, TCG Crossover
13:40 Interactive discussion and Q&A
13:55 Key Insight Case Study with Q&A: Top 5 CEO Issues in Collaboration Transactions: Sleep Better at Night
In this session we'll discuss key strategic considerations for biotech CEOs contemplating collaboration transactions with a big pharma partner. We will cover a preview of the road ahead in terms of baseline deal considerations and an effective process. We will discuss maximizing upside potential for these deals and preserving exit value downstream, including discussion around collaboration scope, exclusivity, financials and change of control.
Ken Krisko, Attorney at Law, Cooley
Geoff Spolyar, Attorney at Law, Cooley
14:15 General Discussion (suggested topics but not limited to)
15:00 Close Biotech Start Up CEO Forum